Pharmexa buys human papilloma virus patents

New York, June 6 - Pharmexa A/S said it acquired the portfolio of intellectual property rights covering T cell epitopes from human papilloma virus from Seed Capital Investments BV.

The move strengthens Pharmexa-Epimmune's patent protection for human papilloma virus and gives Pharmexa-Epimmune direct control of the strategy for these patents.

In addition, Pharmexa-Epimmune will not have to make future milestone and royalty payments to Seed Capital.

Pharmexa-Epimmune previously had a licensing agreement with Seed Capital.

The human papilloma virus epitopeswhich are part of the EP2230 program Pharmexa-Epimmune has out-licensed to Innogenetics.

Located in Hørsholm, Denmark, Pharmexa develops immunotherapy and vaccines for the treatment of chronic and infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.